Related Experiment Videos
[Tuberculosis during treatment by TNFalpha-inhibitors]
Christophe Strady1, Pascal Brochot2, Kamel Ainine1
1Service de médecine interne et des maladies infectieuses, Hôpital Robert Debré, Reims (51).
Presse Medicale (Paris, France : 1983)
|November 7, 2006
Summary
Anti-tumor necrosis factor (TNF) therapies can increase tuberculosis risk, often presenting as severe, disseminated forms. Early detection and management guidelines are crucial for patient safety during TNF inhibitor treatment.
Area of Science:
- Immunology
- Infectious Diseases
- Pharmacology
Background:
- Anti-tumor necrosis factor (TNF) therapies are used for inflammatory conditions.
- Tuberculosis (TB) is a significant global health concern.
- The interplay between TNF inhibitors and TB risk requires careful consideration.
Observation:
- Tuberculosis during anti-TNF therapy often manifests as severe, extrapulmonary, or disseminated disease.
- Paradoxical reactions, including TB, can occur even after discontinuing TNF inhibitors, suggesting immune restoration.
- Adverse drug reaction reports and epidemiological studies indicate an increased risk of TB with TNF inhibitor use.
Findings:
- Experimental studies support the association between TNF inhibitors and an elevated risk of tuberculosis.
- Clinical observations highlight the severe and potentially life-threatening nature of TB in patients on anti-TNF treatment.
- The risk appears linked to the modulation of the immune system by TNF inhibitors.
Implications:
- Implementing specific guidelines for TB prevention and management in patients receiving anti-TNF therapy is essential.
- Proactive screening for tuberculosis before and during anti-TNF treatment is recommended.
- International guidelines, such as those from France and Spain, aim to mitigate TB incidence in this patient population.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Pulmonary Tuberculosis I
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:28Pulmonary Tuberculosis V
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
01:26Pulmonary Tuberculosis IV
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
01:31Pulmonary Tuberculosis III
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
The first classification is based on the development of the disease, and it includes the following categories:
01:28Pulmonary Tuberculosis II
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...